Pgiam/iStock via Getty Images
Ardelyx (ARDX) shares continued to climb on Friday as Piper Sandler upgraded, noting that the company has reported better-than-expected preliminary sales figures for its bowel disease therapy Ibsrela, which led to more than a ~20% jump in its stock in the prior session.